Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 89

Similar articles for PubMed (Select 24714773)

1.

The role of relative lymphocyte count as a biomarker for the effect of catumaxomab on survival in malignant ascites patients: results from a phase II/III study.

Heiss MM, Ströhlein MA, Bokemeyer C, Arnold D, Parsons SL, Seimetz D, Lindhofer H, Schulze E, Hennig M.

Clin Cancer Res. 2014 Jun 15;20(12):3348-57. doi: 10.1158/1078-0432.CCR-13-2351. Epub 2014 Apr 8.

PMID:
24714773
2.

The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: Results of a prospective randomized phase II/III trial.

Heiss MM, Murawa P, Koralewski P, Kutarska E, Kolesnik OO, Ivanchenko VV, Dudnichenko AS, Aleknaviciene B, Razbadauskas A, Gore M, Ganea-Motan E, Ciuleanu T, Wimberger P, Schmittel A, Schmalfeldt B, Burges A, Bokemeyer C, Lindhofer H, Lahr A, Parsons SL.

Int J Cancer. 2010 Nov 1;127(9):2209-21. doi: 10.1002/ijc.25423.

3.

Relative lymphocyte count is a prognostic parameter in cancer patients with catumaxomab immunotherapy.

Ströhlein MA, Lefering R, Bulian DR, Heiss MM.

Med Hypotheses. 2014 Mar;82(3):295-9. doi: 10.1016/j.mehy.2013.12.014. Epub 2013 Dec 27.

PMID:
24411128
4.

Deterioration in quality of life (QoL) in patients with malignant ascites: results from a phase II/III study comparing paracentesis plus catumaxomab with paracentesis alone.

Wimberger P, Gilet H, Gonschior AK, Heiss MM, Moehler M, Oskay-Oezcelik G, Al-Batran SE, Schmalfeldt B, Schmittel A, Schulze E, Parsons SL.

Ann Oncol. 2012 Aug;23(8):1979-85. doi: 10.1093/annonc/mds178. Epub 2012 Jun 24.

5.

Humoral response to catumaxomab correlates with clinical outcome: results of the pivotal phase II/III study in patients with malignant ascites.

Ott MG, Marmé F, Moldenhauer G, Lindhofer H, Hennig M, Spannagl R, Essing MM, Linke R, Seimetz D.

Int J Cancer. 2012 May 1;130(9):2195-203. doi: 10.1002/ijc.26258. Epub 2011 Sep 27.

6.

Catumaxomab: in malignant ascites.

Frampton JE.

Drugs. 2012 Jul 9;72(10):1399-410. doi: 10.2165/11209040-000000000-00000. Review.

PMID:
22676343
7.

Catumaxomab with and without prednisolone premedication for the treatment of malignant ascites due to epithelial cancer: results of the randomised phase IIIb CASIMAS study.

Sehouli J, Pietzner K, Wimberger P, Vergote I, Rosenberg P, Schneeweiss A, Bokemeyer C, Salat C, Scambia G, Berton-Rigaud D, Santoro A, Cervantes A, Trédan O, Tournigand C, Colombo N, Dudnichenko AS, Westermann A, Friccius-Quecke H, Lordick F.

Med Oncol. 2014 Aug;31(8):76. doi: 10.1007/s12032-014-0076-7. Epub 2014 Jun 26.

PMID:
24965536
8.

Catumaxomab--trifunctional anti-EpCAM antibody used to treat malignant ascites.

Bokemeyer C.

Expert Opin Biol Ther. 2010 Aug;10(8):1259-69. doi: 10.1517/14712598.2010.504706. Review.

PMID:
20624115
9.

Regression of liver metastases after treatment with intraperitoneal catumaxomab for malignant ascites due to breast cancer.

Petrelli F, Borgonovo K, Lonati V, Elia S, Barni S.

Target Oncol. 2013 Dec;8(4):291-4. doi: 10.1007/s11523-012-0240-y. Epub 2012 Nov 30.

PMID:
23197249
10.

Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody: a phase I/II study.

Burges A, Wimberger P, Kümper C, Gorbounova V, Sommer H, Schmalfeldt B, Pfisterer J, Lichinitser M, Makhson A, Moiseyenko V, Lahr A, Schulze E, Jäger M, Ströhlein MA, Heiss MM, Gottwald T, Lindhofer H, Kimmig R.

Clin Cancer Res. 2007 Jul 1;13(13):3899-905.

11.

Catumaxomab: malignant ascites: unjustified marketing authorisation.

[No authors listed]

Prescrire Int. 2010 Oct;19(109):207-9.

PMID:
21180374
12.

Catumaxomab for the treatment of malignant ascites in patients with chemotherapy-refractory ovarian cancer: a phase II study.

Berek JS, Edwards RP, Parker LP, DeMars LR, Herzog TJ, Lentz SS, Morris RT, Akerley WL, Holloway RW, Method MW, Plaxe SC, Walker JL, Friccius-Quecke H, Krasner CN.

Int J Gynecol Cancer. 2014 Nov;24(9):1583-9. doi: 10.1097/IGC.0000000000000286.

PMID:
25254563
13.

Immunomonitoring results of a phase II/III study of malignant ascites patients treated with the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3).

Jäger M, Schoberth A, Ruf P, Hess J, Hennig M, Schmalfeldt B, Wimberger P, Ströhlein M, Theissen B, Heiss MM, Lindhofer H.

Cancer Res. 2012 Jan 1;72(1):24-32. doi: 10.1158/0008-5472.CAN-11-2235. Epub 2011 Nov 1.

14.

Re-challenge with catumaxomab in patients with malignant ascites: results from the SECIMAS study.

Pietzner K, Vergote I, Santoro A, Chekerov R, Marmé F, Rosenberg P, Martinius H, Friccius-Quecke H, Sehouli J.

Med Oncol. 2014 Dec;31(12):308. doi: 10.1007/s12032-014-0308-x. Epub 2014 Nov 4.

PMID:
25367854
15.

Review of catumaxomab in the treatment of malignant ascites.

Sebastian M.

Cancer Manag Res. 2010 Nov 8;2:283-6. doi: 10.2147/CMR.S14115.

16.

Intraperitoneal catumaxomab therapy in a cirrhotic patient with malignant ascites due to urethelial carcinoma: a case report.

Krawczyk M, Zimmermann S, Vidacek D, Lammert F.

Onkologie. 2012;35(10):592-4. doi: 10.1159/000342670. Epub 2012 Sep 18.

PMID:
23038231
17.

Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients.

Ruf P, Kluge M, Jäger M, Burges A, Volovat C, Heiss MM, Hess J, Wimberger P, Brandt B, Lindhofer H.

Br J Clin Pharmacol. 2010 Jun;69(6):617-25. doi: 10.1111/j.1365-2125.2010.03635.x.

18.

Dramatic Response to Catumaxomab Treatment for Malign Ascites Related to Renal Cell Carcinoma With Sarcomotoid Differentiation.

Pilanci KN, Ordu C, Akpinar H, Balci C, Başsülü N, Köksal UI, Elbüken F, Okutur K, Bülbül G, Sağlam S, Demir G.

Am J Ther. 2014 Apr 11. [Epub ahead of print]

PMID:
24732906
19.
20.

Development and approval of the trifunctional antibody catumaxomab (anti-EpCAM x anti-CD3) as a targeted cancer immunotherapy.

Seimetz D, Lindhofer H, Bokemeyer C.

Cancer Treat Rev. 2010 Oct;36(6):458-67. doi: 10.1016/j.ctrv.2010.03.001. Epub 2010 Mar 27. Review.

PMID:
20347527
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk